Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/103826
Title: | A selective p53 activator and anticancer agent to improve colorectal cancer therapy | Authors: | Ramos, Helena Soares, Maria I. L. Silva, Joana Raimundo, Liliana Calheiros, Juliana Gomes, Célia Reis, Flávio Monteiro, Filipe A. Nunes, Cláudia Reis, Salette Bosco, Bartolomeo Piazza, Silvano Domingues, Lucília Chlapek, Petr Vlcek, Petr Fabian, Pavel Rajado, Ana Teresa Carvalho, A. T. P. Veselska, Renata Inga, Alberto Melo, Teresa M. V. D. Pinho e Saraiva, Lucília |
Keywords: | anticancer drug; colorectal cancer; p53 activator; targeted therapy | Issue Date: | 13-Apr-2021 | Publisher: | Elsevier | Project: | UIDB/50006/2020 UID/BIO/04469/2019 UIDB/04539/2020 UIDP/04539/2020 BioTecNorte operation (NORTE-01-0145-FEDER- 000004) Porto Neurosciences and Neurologic Disease Research Initiative at I3S (Norte-01-0145-FEDER-000008) Masaryk University (Project MUNI/A/1127/2019) Ministry of Education, Youth and Sports of the Czech Republic (project nos. LQ1605 and LM2018125) SFRH/BD/119144/2016 SFRH/BD/117949/2016 Fondazione AIRC (IG#18985, A.I.) Programa Operacional Potencial Humano (POCH), specifically the BiotechHealth Programme (Doctoral Programme on Cellular and Molecular Biotechnology Applied to Health Sciences, PD/ 00016/2012). UIDB/00313/2020 UIDP/00313/2020 |
Serial title, monograph or event: | Cell Reports | Volume: | 35 | Issue: | 2 | Abstract: | Impairment of the p53 pathway is a critical event in cancer. Therefore, reestablishing p53 activity has become one of the most appealing anticancer therapeutic strategies. Here, we disclose the p53-activating anticancer drug (3S)-6,7-bis(hydroxymethyl)-5-methyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole (MANIO). MANIO demonstrates a notable selectivity to the p53 pathway, activating wild-type (WT)p53 and restoring WT-like function to mutant (mut)p53 in human cancer cells. MANIO directly binds to the WT/mutp53 DNA-binding domain, enhancing the protein thermal stability, DNA-binding ability, and transcriptional activity. The high efficacy of MANIO as an anticancer agent toward cancers harboring WT/mutp53 is further demonstrated in patient-derived cells and xenograft mouse models of colorectal cancer (CRC), with no signs of undesirable side effects. MANIO synergizes with conventional chemotherapeutic drugs, and in vitro and in vivo studies predict its adequate drug-likeness and pharmacokinetic properties for a clinical candidate. As a single agent or in combination, MANIO will advance anticancer-targeted therapy, particularly benefiting CRC patients harboring distinct p53 status. | URI: | https://hdl.handle.net/10316/103826 | ISSN: | 22111247 | DOI: | 10.1016/j.celrep.2021.108982 | Rights: | openAccess |
Appears in Collections: | I&D CQC - Artigos em Revistas Internacionais I&D ICBR - Artigos em Revistas Internacionais I&D CIBB - Artigos em Revistas Internacionais I&D CNC - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S2211124721002965-main.pdf | 5.01 MB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
10
checked on May 2, 2023
Page view(s)
113
checked on Oct 16, 2024
Download(s)
44
checked on Oct 16, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License